Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

A sight loss organisation’s services in Scotland have been awarded a cash boost of nearly £100,000 for the next three years.

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...